Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
In Reply: The purpose of our Editorial was
to discuss the results of the ancrod trial and not the relative efficacy of
aspirin in acute stroke. Aspirin has not been approved by the US Food and
Drug Administration to treat acute stroke.
The relative benefits and safety of aspirin either combined with or
in comparison to ancrod, tPA, or any other new stroke therapy can only be
determined from a randomized controlled trial.
Furlan A, Mayberg MR. Aspirin in Acute Ischemic Stroke—Reply. JAMA. 2000;284(11):1379. doi:10.1001/jama.284.11.1378